GLPG1205 clinical trials
Also written GLPG1205.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses GLPG1205 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GLPG1205
- 4
Studies by the year they started
8 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses GLPG1205 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 2Galapagos NVNCT03725852Written as GLPG1205
- Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205CompletedPhase 1Galapagos NVNCT04704739Written as GLPG1205 film-coated tablets
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male SubjectsCompletedPhase 1Galapagos NVNCT04532567Written as GLPG1205
- This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy SubjectsCompletedPhase 1Galapagos NVNCT03102567Written as GLPG1205 50mg q.d.
- A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male SubjectsCompletedPhase 1Galapagos NVNCT02623296Written as GLPG1205
- Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative ColitisCompletedPhase 2Galapagos NVNCT02337608Written as GLPG1205
- Oral Bioavailability of Solid Formulation of GLPG1205 With and Without FoodCompletedPhase 1Galapagos NVNCT02143856Written as 100 mg GLPG1205
- First-in-Human Single and Multiple Dose of GLPG1205CompletedPhase 1Galapagos NVNCT01887106Written as GLPG1205 single ascending doses, oral suspension